Geriatric Medicine - Market Insights, Competitive Landscape, and Market Forecast - 2034

Published Date : 2026
Pages : 150
Region : Global,
Delivery Timeline : 24 Hours

Geriatric Medicine Market Summary

  • The Geriatric Medicine market size is estimated at USD 145 billion in 2025 and is projected to reach USD 250 billion by 2034. Growth is anchored in the rapidly aging global population, the rising burden of chronic and age-related diseases, and the continued introduction of novel therapies for conditions common in older adults.
  • The global Geriatric Medicine market is growing at a CAGR of 6.3% during the forecast period from 2026 to 2034.
  • By indication, the cardiovascular diseases segment dominated the Geriatric Medicine market with a 27% share in 2025.
  • By route of administration, the oral segment dominated the Geriatric Medicine market with a share of 68% in 2025.
  • By distribution channel, the retail pharmacies segment dominated the Geriatric Medicine market with a share of 46% in 2025.
  • By product type, the branded segment dominated the Geriatric Medicine market with a share of 55% in 2025.
  • North America dominated the global Geriatric Medicine market revenue with a share of 38% in 2025, representing the highest regional market share globally.

Geriatric medicine encompasses the pharmaceuticals, vaccines, and therapies used to prevent, treat, and manage the diseases and conditions that commonly affect older adults. The category spans therapies across the major age-related disease areas, including cardiovascular disease, cancer, neurological disorders such as Alzheimer's disease, Parkinson's disease, and dementia, musculoskeletal disorders such as osteoarthritis and osteoporosis, diabetes, respiratory disease, and other conditions, together with vaccines for older adults such as influenza, pneumococcal, shingles, and respiratory syncytial virus vaccines. These medicines are developed and marketed by leading pharmaceutical companies including Pfizer, Novartis, Roche, Johnson & Johnson, Merck, AbbVie, AstraZeneca, Sanofi, Eli Lilly, and Bayer, and by generic and biosimilar manufacturers. Geriatric medicines are delivered through oral, injectable, topical, and other routes, and distributed through hospital, retail, and online pharmacies, in both branded and generic forms. Older adults are the largest consumers of medicines, frequently managing multiple chronic conditions simultaneously, a situation known as multimorbidity and polypharmacy. Over the past decade, the field has advanced with novel therapies for age-related diseases, including disease-modifying treatments for Alzheimer's disease and new vaccines for older adults, while generics and biosimilars have expanded access. Driven by the rapidly aging global population and the rising burden of chronic disease, geriatric medicine is a large and steadily growing area of the pharmaceutical market.

Geriatric Medicine Market Key Growth Drivers

  • The rapidly aging global population is the primary driver, with the World Health Organization projecting the number of people aged 60 and older to reach 2.1 billion by 2050, expanding the population requiring medical care.
  • The rising burden of chronic and age-related diseases, including cardiovascular disease, cancer, dementia, diabetes, and musculoskeletal disorders, is expanding demand for geriatric medicines.
  • The high prevalence of multimorbidity and polypharmacy among older adults, who often manage multiple chronic conditions, increases medication use.
  • The introduction of novel therapies for age-related diseases, including disease-modifying treatments for Alzheimer's disease and new vaccines for older adults, is expanding the treatment landscape.
  • Expanding healthcare access, insurance coverage, and long-term care infrastructure is broadening access to geriatric medicines.
  • The growth of generics and biosimilars is expanding access to affordable medicines for the large elderly population, particularly in emerging markets.
  • The convergence of population aging, rising chronic disease burden, and therapeutic innovation is expected to sustain steady growth in the global Geriatric Medicine market through 2034.

Key Companies in Geriatric Medicine Market

The competitive landscape is led by the following active developers and manufacturers of medicines and vaccines used in geriatric care:

  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • AstraZeneca plc
  • Sanofi S.A.
  • Eli Lilly and Company
  • Bayer AG, and others

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Geriatric Medicine Market Size

The following snapshot summarizes the principal report metrics for the Geriatric Medicine market.

Report Metrics

Details

2025 Market Size

USD 145 billion

2034 Projected Market Size

USD 250 billion

Growth Rate (2026-2034)

6.3% CAGR

Largest Market

North America

Fastest Growing Market

Asia-Pacific

Market Structure

Fragmented

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Geriatric Medicine Market

Geriatric Medicine Market Drivers

  • Rapidly Aging Global Population: The rapid aging of the global population is the foundational driver of the geriatric medicine market. According to the World Health Organization, the number of people aged 60 and older is rising rapidly and is projected to reach 2.1 billion by 2050, with the number aged 80 and older growing even faster, while by 2030 one in six people worldwide will be aged 60 or older. Older adults are the largest consumers of medicines, requiring treatment for a wide range of chronic and age-related conditions, and the growth of this population directly expands the demand for geriatric medicines. Aging is occurring across both developed and developing countries, and in several countries, including Japan, the elderly already constitute a very large share of the population. As populations continue to age worldwide, the expanding elderly population is expected to be the leading driver of geriatric medicine demand across the forecast period, generating sustained and growing consumption of medicines and vaccines.
  • Rising Burden of Chronic and Age-Related Diseases: The rising burden of chronic and age-related diseases is a powerful driver of geriatric medicine demand. Older adults carry a high and rising prevalence of cardiovascular disease, cancer, neurological disorders such as Alzheimer's disease and Parkinson's disease, diabetes, musculoskeletal disorders such as osteoarthritis and osteoporosis, and respiratory disease, each of which requires ongoing treatment. Cardiovascular disease and cancer are leading causes of death among older adults, and the prevalence of dementia and other age-related conditions is rising with population aging. The chronic nature of these conditions generates long-term, recurring treatment, and the growing number of older adults with these diseases expands the treated population. As the burden of chronic and age-related disease continues to rise with population aging, this trend is expected to be a significant driver of geriatric medicine demand across the forecast period.
  • High Prevalence of Multimorbidity and Polypharmacy: The high prevalence of multimorbidity and polypharmacy among older adults is a substantial driver of geriatric medicine demand. Older adults frequently live with multiple chronic conditions simultaneously, and the management of multimorbidity often requires several medicines taken concurrently, a situation known as polypharmacy. This increases the volume of medicines consumed per patient and expands overall demand. The management of conditions such as hypertension, diabetes, high cholesterol, arthritis, and others in the same patient drives sustained, recurring medication use. While polypharmacy raises important safety and adherence considerations, it reflects and drives the high medication use characteristic of the elderly population. As the number of older adults with multiple chronic conditions grows, multimorbidity and polypharmacy are expected to be an important driver of geriatric medicine demand across the forecast period.
  • Introduction of Novel Therapies for Age-Related Diseases: The introduction of novel therapies for age-related diseases is a defining driver of the geriatric medicine market. Recent years have seen significant innovation in therapies for conditions that predominantly affect older adults, including disease-modifying anti-amyloid antibodies for Alzheimer's disease such as lecanemab and donanemab, and new vaccines for older adults, including respiratory syncytial virus vaccines and improved influenza, pneumococcal, and shingles vaccines. Novel therapies across oncology, cardiovascular disease, and other areas continue to expand treatment options for older adults. These innovations address large, previously underserved populations, often command premium pricing, and expand the treatment landscape. Manufacturers continue to invest in therapies and vaccines targeting age-related diseases. As novel therapies and vaccines for age-related diseases continue to reach the market and address large elderly populations, therapeutic innovation is expected to be a significant driver of geriatric medicine market growth across the forecast period.
  • Expanding Healthcare Access and Long-Term Care Infrastructure: Expanding healthcare access, insurance coverage, and long-term care infrastructure is a substantial driver of geriatric medicine demand. Growing insurance coverage, including public programs for older adults, and expanding access to healthcare and long-term care services increase the diagnosis and treatment of age-related conditions and the consumption of medicines. The growth of nursing homes, assisted living, and home healthcare, together with improved access to primary and specialty care, broadens the delivery of geriatric medicines. In many countries, government programs and initiatives specifically support the health of older adults. Rising awareness, screening, and management of chronic disease further increase treatment. As healthcare access and long-term care infrastructure continue to expand, particularly for aging populations, this expansion is expected to be an important driver of geriatric medicine market growth across the forecast period.
  • Growth of Generics and Biosimilars: The growth of generics and biosimilars is a substantial driver of access and volume in the geriatric medicine market. Older adults, who consume the largest share of medicines and often on fixed incomes, benefit substantially from lower-cost generic and biosimilar medicines, and the widespread availability of generics for common chronic conditions such as hypertension, high cholesterol, and diabetes expands access and adherence. The expansion of biosimilars for high-cost biologics used in cancer, inflammatory, and other age-related conditions further broadens access. In emerging markets, generics are central to expanding access to medicines for large and growing elderly populations. While generics and biosimilars compress prices, they expand volume and access substantially. As generics and biosimilars continue to expand access to affordable medicines for the elderly, this growth is expected to be an important driver of geriatric medicine market volume across the forecast period, particularly in emerging markets.

Geriatric Medicine Market Restraints

Despite steady momentum, the Geriatric Medicine market faces material constraints. Polypharmacy in older adults raises significant risks of adverse drug reactions, drug-drug interactions, and medication errors, which can limit prescribing and require careful management. Age-related changes in pharmacokinetics and pharmacodynamics, including altered drug metabolism and excretion, complicate dosing and increase the risk of adverse effects, and frailty and comorbidity add further complexity. Medication adherence is a persistent challenge among older adults, affected by complex regimens, cognitive impairment, and physical limitations, which can reduce effectiveness. Cost and reimbursement pressures constrain access, particularly for high-cost novel therapies, and pricing pressure, including drug price negotiation under measures such as the Inflation Reduction Act that targets medicines heavily used by the elderly, and generic and biosimilar erosion, compress revenue for established products. The historical underrepresentation of older adults in clinical trials limits evidence for this population. Regulatory requirements for drugs and vaccines are rigorous and costly, and development timelines are long. Finally, uneven healthcare access, affordability constraints, and limited geriatric care infrastructure in some regions can restrict access and adoption across parts of the forecast period.

Geriatric Medicine Market Segment Analysis

The Geriatric Medicine Market is segmented by indication (cardiovascular diseases, oncology, neurological disorders, musculoskeletal disorders, diabetes, respiratory diseases, others), route of administration (oral, injectable, topical, others), distribution channel (retail pharmacies, hospital pharmacies, online pharmacies), product type (branded, generic), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Indication

Dominant Subsegment: Cardiovascular Diseases.

The cardiovascular diseases segment accounted for 27% of the Geriatric Medicine market in 2025. Cardiovascular disease dominates because it is the most prevalent and among the deadliest chronic conditions in older adults, and its treatment involves a large and widely used array of medicines, including antihypertensives, lipid-lowering agents such as statins, anticoagulants and antiplatelets, and heart failure therapies. The high prevalence of hypertension, coronary artery disease, atrial fibrillation, and heart failure among the elderly, and the chronic, lifelong nature of their treatment, drive the largest share of geriatric medicine use. Oncology represents a large and high-value indication, driven by the rising cancer burden in older adults and the use of high-cost targeted therapies, immunotherapies, and other agents, and it is a major growth area. Neurological disorders, including Alzheimer's disease, Parkinson's disease, and dementia, represent a large and rapidly growing indication, reinforced by new disease-modifying therapies, and diabetes, musculoskeletal disorders, respiratory disease, and other indications add substantial demand. Nonetheless, the prevalence, chronicity, and broad treatment of cardiovascular disease in older adults secure the leadership of this segment across the forecast period, with oncology and neurology growing strongly.

By Route of Administration

Dominant Subsegment: Oral.

The oral segment accounted for 68% of the Geriatric Medicine market in 2025. Oral administration dominates because the majority of medicines used to manage the chronic conditions common in older adults, including antihypertensives, lipid-lowering agents, oral antidiabetics, analgesics, and many central nervous system and other agents, are taken orally. Oral medicines are convenient, suitable for self-administration and long-term chronic use, and widely available as low-cost generics, making them the mainstay of geriatric pharmacotherapy and driving the largest share of medication use. The injectable segment is large and growing in value, encompassing high-value biologics, oncology therapies, vaccines, and injectable treatments for age-related diseases, including anti-amyloid antibodies for Alzheimer's disease, and it is a key area of innovation. The topical route serves dermatologic, musculoskeletal, and localized conditions, and other routes, including inhaled and transdermal, add further demand, particularly for respiratory and pain management. Nonetheless, the convenience, suitability for chronic use, and broad availability of oral medicines secure the leadership of the oral segment across the forecast period, with injectables growing in value.

By Distribution Channel

Dominant Subsegment: Retail Pharmacies.

The retail pharmacies segment accounted for 46% of the Geriatric Medicine market in 2025. Retail pharmacies dominate because older adults obtain the majority of their chronic, self-administered medicines, including cardiovascular, diabetes, and pain medicines, through community and chain retail pharmacies, which provide convenient, recurring access to prescriptions and over-the-counter products. The high volume of ongoing outpatient chronic-disease prescriptions among the elderly drives the largest share of distribution through retail pharmacies. Hospital pharmacies represent a large channel, dispensing medicines for inpatient care, acute conditions, and high-cost specialty therapies, including many oncology and injectable treatments, and are important for complex and initiated therapies. Online pharmacies are a rapidly growing channel, offering convenience, home delivery, and often lower prices, which are particularly valuable for older adults with mobility limitations managing chronic medications. Nonetheless, the high volume of recurring outpatient chronic-disease prescriptions dispensed through retail pharmacies secures the leadership of this segment across the forecast period, with online pharmacies growing rapidly.

By Product Type

Dominant Subsegment: Branded.

The branded segment accounted for 55% of the Geriatric Medicine market in 2025. Branded medicines dominate by value because high-cost, in-patent branded therapies, particularly novel oncology agents, biologics, disease-modifying treatments for Alzheimer's disease, and new vaccines for older adults, generate the majority of market revenue despite lower volumes. The premium pricing of innovative branded therapies for age-related diseases, and the continued flow of new approvals, sustain the leading revenue share of branded products. The generic segment, including generics and biosimilars, dominates by volume, as the majority of prescriptions filled for older adults, particularly for common chronic conditions such as hypertension, high cholesterol, and diabetes, are low-cost generics that expand access and adherence. Generics and biosimilars are central to affordable care for the elderly and to access in emerging markets, and biosimilar competition is growing for high-cost biologics. Nonetheless, the high value of innovative branded therapies for age-related diseases secures the leadership of the branded segment by revenue across the forecast period, while generics dominate by volume and expand access.

Geriatric Medicine Market Region Analysis

North America accounted for 38% of the global Geriatric Medicine market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the largest and highest-priced pharmaceutical market in the world, a large and growing elderly population, high healthcare spending, and rapid adoption of novel therapies. The United States leads on the strength of high per-capita drug spending, a large aging population, comprehensive coverage for older adults through Medicare, rapid adoption of novel therapies including anti-amyloid antibodies and new vaccines for older adults, and the presence of major developers including Pfizer, Merck, AbbVie, and Eli Lilly. Disease burden is substantial, with a large elderly population affected by cardiovascular disease, cancer, dementia, diabetes, and other age-related conditions. The regulatory environment is highly supportive, with the Food and Drug Administration providing established pathways and a track record of approving novel geriatric-relevant therapies and vaccines. Reimbursement supports treatment, though drug price negotiation under the Inflation Reduction Act, which targets high-cost medicines used by Medicare beneficiaries, is beginning to affect selected products. This combination of market size, aging population, and innovation reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Geriatric Medicine market. The region's elevated CAGR is driven by very large and rapidly aging populations, a rising burden of chronic disease, expanding healthcare access, and growing pharmaceutical markets across China, Japan, India, South Korea, and Southeast Asia. Several countries in the region, including Japan and China, have among the largest and fastest-growing elderly populations in the world, dramatically expanding demand for geriatric medicines. Rising incomes, expanding insurance coverage, and growing healthcare investment are improving access to medicines and vaccines for older adults, and domestic pharmaceutical and generic manufacturing is expanding access. Rising prevalence of cardiovascular disease, cancer, diabetes, and dementia, together with growing awareness and diagnosis, further increases demand. Both multinational and regional companies are expanding their presence. Government initiatives to address aging populations further support growth. The combination of large and rapidly aging populations, rising disease burden, expanding access, and growing pharmaceutical capacity positions Asia-Pacific as the highest-growth region over the forecast period.

Geriatric Medicine Market Regional Commentary

North America

North America accounted for 38% of the global Geriatric Medicine market revenue in 2025. The United States dominates the region on the strength of the largest pharmaceutical market, a large aging population, comprehensive coverage for older adults, and rapid adoption of novel therapies, while Canada contributes through public drug coverage and Mexico expands access within its growing healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom, and has among the oldest populations in the world. Growth is supported by a high burden of age-related disease, established healthcare systems, advanced generic and biosimilar adoption, and the presence of major developers such as Novartis, Roche, Sanofi, Bayer, and AstraZeneca, while the European Medicines Agency provides established regulatory pathways.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large and rapidly aging populations, a rising burden of chronic disease, expanding healthcare access, and growing pharmaceutical markets across China, Japan, India, South Korea, and Southeast Asia. Japan's aged population, China's rapid aging, and India's generic manufacturing are broadening demand and access.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Aging populations, a rising burden of chronic disease, improving healthcare access, and expanding availability of generics are broadening adoption, while generics play an important role in expanding access to medicines for older adults.

Geriatric Medicine Market Competitive Landscape

The Geriatric Medicine market is classified as Fragmented. A broad field of large pharmaceutical companies, vaccine manufacturers, and generic and biosimilar producers competes across the many disease areas relevant to older adults, led by Pfizer, Novartis, Roche, Johnson & Johnson, and Merck, with AbbVie, AstraZeneca, Sanofi, Eli Lilly, and Bayer holding major franchises and numerous generic manufacturers competing on volume and access. The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Fragmented, spanning many large pharmaceutical companies, vaccine makers, and generic and biosimilar manufacturers across multiple disease areas.
  • Leading players: Pfizer, Novartis, Roche, Johnson & Johnson, and Merck anchor the top tier, with AbbVie, AstraZeneca, Sanofi, Eli Lilly, and Bayer holding major franchises.
  • Geographic reach: Leaders operate global commercial and manufacturing networks, with strong positions across North America, Europe, and Asia-Pacific.
  • Product portfolio strength: Top players hold broad portfolios across cardiovascular, oncology, neurology, diabetes, and vaccines relevant to older adults.
  • Pipeline strength: Deep pipelines in oncology, neurology including Alzheimer's disease, cardiometabolic disease, and vaccines for older adults.
  • Strategic partnerships: Extensive collaborations, licensing, and acquisitions across age-related disease areas shape the competitive landscape.
  • M&A activity: Significant consolidation and acquisitions continue, particularly in oncology, neurology, and cardiometabolic disease.
  • Manufacturing capabilities: Large-scale pharmaceutical, biologic, and vaccine manufacturing, and generic production capacity, are key competitive strengths.
  • Innovation focus: Disease-modifying therapies for Alzheimer's disease, novel oncology and cardiometabolic agents, vaccines for older adults, and biosimilars.

Geriatric Medicine Market Recent Developmental Activities

  • In 2023, the FDA approved lecanemab (Leqembi) from Eisai and Biogen for Alzheimer's disease, followed by donanemab (Kisunla) from Eli Lilly in 2024. Strategic significance: Introduces disease-modifying therapies for a major age-related neurological disease and opens a large new market.
  • In 2023, the FDA approved the first respiratory syncytial virus vaccines for older adults, Arexvy from GSK and Abrysvo from Pfizer, with expanded eligibility following in 2024. Strategic significance: Creates a large new vaccine market for a significant respiratory threat to older adults.
  • In 2023 and 2024, GLP-1 receptor agonists for diabetes and obesity, including therapies from Novo Nordisk and Eli Lilly, expanded rapidly, benefiting many older adults with cardiometabolic disease. Strategic significance: Expands cardiometabolic treatment options widely used in the aging population.
  • In 2023 and 2024, oncology therapies including targeted agents, immunotherapies, and antibody-drug conjugates expanded across cancers common in older adults. Strategic significance: Broadens high-value treatment options for the large elderly oncology population.
  • In 2023 and 2024, shingles and pneumococcal vaccination for older adults expanded, including broader recommendations and new vaccines. Strategic significance: Strengthens preventive care and vaccine markets for older adults.
  • In 2024 and 2025, drug price negotiation under the Inflation Reduction Act began to affect selected high-cost medicines heavily used by the Medicare elderly population. Strategic significance: Introduces new pricing pressure on medicines central to geriatric care and influences manufacturer strategy.
  • In 2023 and 2024, biosimilars of major biologics, including adalimumab and others used in age-related inflammatory and other conditions, expanded in the United States. Strategic significance: Expands lower-cost access to biologic therapy for older adults and intensifies competition.
  • In 2023 and 2024, cardiovascular therapies, including anticoagulants and lipid-lowering agents, continued to expand and face growing generic competition. Strategic significance: Sustains the large cardiovascular medicine market for older adults while compressing prices for established products.
  • In 2023 and 2024, companies advanced pipelines in neurology, oncology, and cardiometabolic disease targeting age-related conditions. Strategic significance: Reinforces the strategic importance of age-related diseases to the pharmaceutical industry.
  • In 2023 and 2024, home healthcare, digital health, and medication management solutions for older adults expanded, supporting adherence and chronic disease management. Strategic significance: Improves the delivery and adherence of geriatric medicines.
  • In 2023 and 2024, generic manufacturers expanded access to affordable medicines for chronic conditions in older adults, particularly in emerging markets. Strategic significance: Broadens access to essential medicines for large and growing elderly populations.
  • In 2023 and 2024, the World Health Organization and health systems reinforced the priority of healthy aging and care for older adults amid rapid population aging. Strategic significance: Underscores the large and growing addressable population for geriatric medicine.

Geriatric Medicine Market Segmentation

  • Geriatric Medicine Market by Indication
    • Cardiovascular Diseases
    • Oncology
    • Neurological Disorders
    • Musculoskeletal Disorders
    • Diabetes
    • Respiratory Diseases
    • Others
  • Geriatric Medicine Market by Route of Administration
    • Oral
    • Injectable
    • Topical
    • Others
  • Geriatric Medicine Market by Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Geriatric Medicine Market by Product Type
    • Branded
    • Generic

Geriatric Medicine Market Assessment by Geography

  • North America Geriatric Medicine Market Assessment
    • United States Geriatric Medicine Market Size in USD million (2023-2034)
    • Canada Geriatric Medicine Market Size in USD million (2023-2034)
    • Mexico Geriatric Medicine Market Size in USD million (2023-2034)
  • Europe Geriatric Medicine Market Assessment
    • Germany Geriatric Medicine Market Size in USD million (2023-2034)
    • United Kingdom Geriatric Medicine Market Size in USD million (2023-2034)
    • France Geriatric Medicine Market Size in USD million (2023-2034)
    • Italy Geriatric Medicine Market Size in USD million (2023-2034)
    • Spain Geriatric Medicine Market Size in USD million (2023-2034)
    • Rest of Europe Geriatric Medicine Market Size in USD million (2023-2034)
  • Asia-Pacific Geriatric Medicine Market Assessment
    • China Geriatric Medicine Market Size in USD million (2023-2034)
    • Japan Geriatric Medicine Market Size in USD million (2023-2034)
    • India Geriatric Medicine Market Size in USD million (2023-2034)
    • Australia Geriatric Medicine Market Size in USD million (2023-2034)
    • South Korea Geriatric Medicine Market Size in USD million (2023-2034)
    • Rest of Asia-Pacific Geriatric Medicine Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Geriatric Medicine Market Assessment
    • Middle East Geriatric Medicine Market Size in USD million (2023-2034)
    • Africa Geriatric Medicine Market Size in USD million (2023-2034)
    • South America Geriatric Medicine Market Size in USD million (2023-2034)

Geriatric Medicine Market Recent Industry Trends and Milestones (2023-2026):

Category

Key Developments

Geriatric Medicine Market Product Approval

The FDA approved lecanemab (Leqembi, 2023) and donanemab (Kisunla, 2024) for Alzheimer's disease; the first RSV vaccines for older adults, Arexvy and Abrysvo, were approved (2023) with expanded eligibility (2024); GLP-1 therapies and oncology agents expanded; the FDA and EMA advanced pathways for geriatric-relevant therapies.

Geriatric Medicine Market Product Expansion

Anti-amyloid antibodies, RSV, shingles, and pneumococcal vaccines, GLP-1 therapies, oncology agents, and cardiovascular therapies expanded across older-adult populations; biosimilars of major biologics expanded access; generics broadened access to chronic-disease medicines.

Geriatric Medicine Market Product Investment

Companies invested in neurology, including Alzheimer's disease, oncology, cardiometabolic disease, and vaccines for older adults through pipelines, acquisitions, and licensing; generic manufacturers expanded access; home healthcare and medication management solutions expanded.

Geriatric Medicine Market Company Strategy

Pfizer Inc. and GSK plc: RSV and other vaccines for older adults. Eli Lilly and Company: Alzheimer's disease and cardiometabolic therapies. Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., and Bayer AG: Oncology, cardiovascular, and other age-related franchises.

Geriatric Medicine Market Emerging Technologies

Disease-modifying anti-amyloid antibodies for Alzheimer's disease; new vaccines for older adults including RSV; GLP-1 and cardiometabolic therapies; novel oncology agents including targeted therapies, immunotherapies, and antibody-drug conjugates; biosimilars; and digital health and medication management for adherence.

Geriatric Medicine Market Startup Funding and Investment Trends

Investment in the geriatric medicine and aging ecosystem has concentrated on therapies targeting the biology of aging, age-related diseases, and healthy longevity. The following companies illustrate recent activity and technology focus.

Company

Total Funding

Funding Stage

Main Product

Core Technology

BioAge Labs, Inc.

Public and venture funding

Public / growth-stage

Metabolic aging and age-related disease pipeline

Aging biology and human data-driven drug discovery

Unity Biotechnology, Inc.

Public and venture funding

Public / growth-stage

Senolytic therapy pipeline

Senolytic medicines targeting cellular senescence in age-related disease

 

Request to unlock the report on the @ Geriatric Medicine Market Insights

 

BioAge Labs is developing therapies for age-related metabolic and other diseases using insights from human aging biology, while Unity Biotechnology develops senolytic medicines designed to target senescent cells implicated in age-related disease. Additional capital continues to flow toward therapies targeting the biology of aging, age-related diseases such as neurodegeneration and metabolic disease, and healthy longevity, reflecting conviction that addressing the underlying mechanisms of aging is a promising source of future value. Collectively, these efforts signal sustained investment in expanding and improving therapies for the large and growing elderly population and in addressing age-related diseases with high unmet need.

Key Takeaways from the Geriatric Medicine Market Report Study

  • Market size analysis for the current geriatric medicine market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global geriatric medicine market.
  • Various opportunities available for competitors in the geriatric medicine market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current geriatric medicine market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for geriatric medicine market growth in the future?

Target audience that can benefit from this geriatric medicine market report study

  • Geriatric Medicine product providers
  • Research organizations and consulting companies
  • Geriatric Medicine-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in geriatric medicines
  • Various end-users who want to know more about the geriatric medicine market and the latest therapeutic developments in the geriatric medicine market.

Frequently Asked Questions

Q1. What is the growth rate of the Geriatric Medicine market?

The Geriatric Medicine market is projected to expand at a CAGR of 6.3% during the forecast period of 2026-2034.

Q2. What is the market size of the Geriatric Medicine market?

The Geriatric Medicine market size is estimated at USD 145 billion in 2025 and is projected to reach USD 250 billion by 2034.

Q3. Which region dominates the Geriatric Medicine market?

North America dominated the Geriatric Medicine market with a 38% share of global revenue in 2025, supported by the largest pharmaceutical market, a large aging population, comprehensive coverage for older adults, rapid adoption of novel therapies, and the presence of leading developers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Geriatric Medicine market?

The principal drivers are the rapidly aging global population, projected by the World Health Organization to reach 2.1 billion people aged 60 and older by 2050; the rising burden of chronic and age-related diseases; the high prevalence of multimorbidity and polypharmacy; and the introduction of novel therapies for age-related diseases, including disease-modifying Alzheimer's treatments and new vaccines for older adults, reinforced by expanding access and the growth of generics and biosimilars.

Q5. Who are the major players in the Geriatric Medicine market?

The major Geriatric Medicine companies in the market include Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., AstraZeneca plc, Sanofi S.A., Eli Lilly and Company, and Bayer AG, among other active developers and generic manufacturers profiled in the Competitive Landscape section. These companies hold broad portfolios across cardiovascular, oncology, neurology, diabetes, and vaccines relevant to older adults.

Tags:

  • Geriatric Medicine
  • Geriatric Medicine Mechanism
  • Geriatric Medicine Companies
  • Geriatric Medicine Medical devices

License Type


Offer

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports